September 09, 2015 9:00am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK) today announced a global license agreement
with The Scripps Research Institute (TSRI) for the development and
commercialization of novel lipoprotein signal peptidase (“Lsp”)
inhibitors developed and discovered using a proprietary high throughput
screening technology funded and exclusively licensed by OPKO from TSRI.
“This technology is one of the best opportunities we have for the
development of specific inhibitors of Lsp, which represents a remarkable
target for the development of broad and novel antimicrobial agents, as
it is highly conserved throughout the bacterial and mycoplasma kingdoms
and no human homologues exist,” said TSRI Professor Dennis Wolan, Ph.D.,
who led the research on this screening platform.
OPKO has agreed to fund additional work in Dr. Wolan’s laboratory at
TSRI and to move as rapidly as possible into clinical trials.
“We are pleased to continue our collaboration with Dr. Wolan and The
Scripps Research Institute to develop the next generation of highly
effective antibiotics,” said Phillip Frost, M.D., Chairman and Chief
Executive Officer. “Our plan is to continue to build on two promising
leads already identified and others using the novel screening technology
developed at Scripps.”
There is a tremendous unmet medical need for new, potent antibiotics.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies. For more information,
visit http://www.opko.com .
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest
independent, not-for-profit organizations focusing on research in the
biomedical sciences. TSRI is internationally recognized for its
contributions to science and health, including its role in laying the
foundation for new treatments for cancer, rheumatoid arthritis,
hemophilia, and other diseases. An institution that evolved from the
Scripps Metabolic Clinic founded by philanthropist Ellen Browning
Scripps in 1924, the institute now employs about 2,700 people on its
campuses in La Jolla, CA, and Jupiter, FL, where its renowned
scientists—including two Nobel laureates—work toward their next
discoveries. The institute's graduate program, which awards PhD degrees
in biology and chemistry, ranks among the top ten of its kind in the
nation. For more information, see www.scripps.edu .
Forward Looking Statements
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding expected benefits of the
technology licensed from Scripps, whether it will enable development of
specific inhibitors of Lsp and result in development of broad and novel
antimicrobial agents and the next generation of highly effective
antibiotics, our ability to build on two promising leads already
identified and others using the novel screening technology, our ability
to advance to clinical trials, as well as other non-historical
statements about our expectations, beliefs or intentions regarding our
business, technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or results to
differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
Annual Reports on Form 10-K filed and to be filed with the Securities
and Exchange Commission and in our other filings with the Securities and
Exchange Commission, as well as the risks inherent in funding,
developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments, that
earlier clinical results of effectiveness and safety may not be
reproducible or indicative of future results, that the technology and
other products under development may fail, may not achieve the expected
results or effectiveness and may not generate data that would support
the approval or marketing of products for the indications being studied
or for other indications, that currently available over-the-counter and
prescription products, as well as products under development by others,
may prove to be as or more effective than our products for the
indications being studied. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150909005534/en/
OPKO Health, Inc.
Investor Relations, 305-575-4100
or
Media
Rooney & Associates
Terry
Rooney, 212-223-0689
or
Rooney
& Associates
Marion Janic, 212-223-4017
Source: OPKO Health, Inc.
Released September 9, 2015
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page